language_icon
EN
HI

Venus Remedies Share price

VENUSREM

1411.3

67.20 (5.00%)
NSE
BSE
Last updated on 2 Jun, 2026 | 09:57 IST
Today's High

1411.30

Today's Low

1355.10

52 Week Low

415.40

52 Week High

1411.30

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Venus Remedies Chart

Venus Remedies Share Key Metrics

Volume
2.42 L
Market Cap
1796.66 CR
LTQ@LTP
10@1411.30
ATP
1395.43
Var Margin
100 %
Circuit Range
1276.9-1411.3
Delivery %
100 %
Value
33.74 CR
ASM/GSM
No
Market Lot
1

Summary

Venus Remedies share price is ₹1411.3 as of 2 Jun, 2026. The stock Venus Remedies intraday movement has stayed between ₹1355.10 and ₹1411.30, while on a 52-week basis,Venus Remedies price 52 week high is ₹1411.30 & its 52 week low is ₹415.40.
In terms of trading activity, Venus Remedies has recorded a volume of 241805 shares, The Venus Remedies has a market cap of ₹13366988 CR. The stock’s Average Traded Price (ATP) stands at ₹1395.43, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 10 @ ₹1411.30.
Venus Remedies operates within a circuit range of ₹1276.90 – ₹1411.30, with a Value of ₹33.74 CR. The Delivery Percentage for the day is 100%. Additionally, Venus Remedies currently falls under the No framework, and trades with a market lot size of 1.

Venus Remedies Fundamentals

View More
P/E Ratio

17.52

P/B Ratio

2.71

Div. Yield

0.74

Sector P/E

69.94

Sector P/B

2.97

Sec. Div. Yield

0.55

Venus Remedies Resistance and Support

Pivot 1344.1

Resistance

First Resistance

1344.1

Second Resistance

1344.1

Third Resistance

1344.1

Support

First Support

1344.1

Second Support

1344.1

Third Support

1344.1

Venus Remedies Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

41.76%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

2.8%

Domestic Institutional Investors

1.2%

Retail

54.24%

Others

0%

Total Promoters
MAR '26
41.76%

Venus Remedies Corporate Actions

DateAgenda
2026-05-26Audited Results
2025-11-10Quarterly Results
2025-05-26Audited Results
2025-02-04Quarterly Results

Venus Remedies News

Venus Remedies Limited

Venus Remedies Ltd recommended a final dividend of Rs.10 per equity share for the financial year 2025-26. The record date for the dividend is August 7, 2026, with payment expected by September 18, 2026, after shareholder approval at the AGM on August 20, 2026.
May 26 2026 22:36:21

Venus Remedies Limited

Venus Remedies Ltd recommended a final dividend of Rs.10 per equity share for the financial year 2025-26. The record date for the dividend is August 7, 2026, with payment expected by September 18, 2026, after shareholder approval at the AGM on August 20, 2026.
May 26 2026 22:35:35

Venus Remedies Ltd - 526953 - Adoption Of MOA & AOA As Per The Companies Act 2013

Venus Remedies board approved several key leadership appointments. Mr. Saransh Chaudhary was appointed as Whole Time Director for five years from May 26, 2026. Dr. (Mrs.) Manu Chaudhary was reappointed as Joint Managing Director for five years from October 1, 2026. Both are subject to shareholder approval.
May 26 2026 22:12:45

Venus Remedies Ltd - 526953 - Announcement under Regulation 30 (LODR)-Change in Management

Venus Remedies appointed Mr. Saransh Chaudhary as Whole Time Director and re-appointed Dr. Manu Chaudhary as Joint Managing Director, both for five-year terms. The board also approved the appointments of two Non-Executive Independent Directors.
May 26 2026 22:08:57

Venus Remedies Ltd - 526953 - Venus Remedies Receives Saudi FDA Approval For Plerixafor - Its First Maketing Authorization For The Specialty Oncology Therapy Globally

Venus Remedies received Saudi FDA approval for Plerixafor, its first global marketing authorization for the specialty oncology therapy. This approval allows the company to commercialize the drug in Saudi Arabia, a key market for high-value specialty injectables.
May 22 2026 11:54:13

Venus Remedies Ltd - 526953 - Corporate Action-Board to consider Dividend

Venus Remedies board scheduled a meeting for May 26, 2026. The agenda includes consideration for a final dividend recommendation for FY26. Post-meeting, the board's decision on the dividend will be announced.
May 15 2026 15:32:40

Venus Remedies Ltd - 526953 - Board Meeting Intimation for Board Meeting Scheduled For 26Th May 2026.

Venus Remedies' Board of Directors will convene on May 26, 2026, to discuss and approve the audited financial results for the quarter and fiscal year ending March 31, 2026. They will also consider recommending a final dividend for the same period.
May 15 2026 15:28:45
Read More

Venus Remedies Management

NamePosition
Pawan ChaudharyChairman & Managing Director
Manu ChaudharyJoint Managing Director
View More

Venus Remedies FAQs

The Buying Price of Venus Remedies share is 1411.3 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Venus Remedies stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Venus Remedies, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Venus Remedies shares is 17.52. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Venus Remedies shares is 2.71. Useful to assess the stock's value relative to its book value.

To assess Venus Remedies’s valuation compare Sector P/E, P/B which are 69.94 & 2.97 with sector averages, along with growth rates and financial metrics.

The Market Cap of Venus Remedies is 1796.66 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Venus Remedies share price is 1411.30 & 415.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Venus Remedies belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost